Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Medpace Holdings's Enterprise Value is €14,418 Mil.
Medpace Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €502 Mil. Therefore, Medpace Holdings's EV-to-EBIT ratio for today is 28.75.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Medpace Holdings's Enterprise Value is €14,418 Mil.
Medpace Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €525 Mil. Therefore, Medpace Holdings's EV-to-EBITDA ratio for today is 27.44.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Medpace Holdings's Enterprise Value is €14,418 Mil.
Medpace Holdings's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was €2,392 Mil. Therefore, Medpace Holdings's EV-to-Revenue ratio for today is 6.03.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Medpace Holdings (FRA:01P) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Medpace Holdings's current Enterprise Value is €14,418 Mil.
Medpace Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €502 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Medpace Holdings's current Enterprise Value is €14,418 Mil.
Medpace Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €525 Mil.
Medpace Holdings's current Enterprise Value is €14,418 Mil.
Medpace Holdings's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2,392 Mil.
Medpace Holdings's current Enterprise Value is €14,418 Mil.
Medpace Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €646 Mil.
Medpace Holdings's current Enterprise Value is €14,418 Mil.
Medpace Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €607 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings Enterprise Value Related Terms
Medpace Holdings Enterprise Value Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:01P vs ICLR, RVTY, CRL: Enterprise Value Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings Enterprise Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Medpace Holdings's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings (FRA:01P) has a Enterprise Value of €14,418 Mil as of Jul. 25, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Medpace Holdings and its competitors.
Is Medpace Holdings' Enterprise Value too high?
Medpace Holdings' current Enterprise Value is €14,418 Mil. Overall, Medpace Holdings has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' Enterprise Value compare to ICLR and RVTY?
Medpace Holdings' Enterprise Value of €14,418 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Diagnostics & Research company?
A good Enterprise Value depends on the Medical Diagnostics & Research industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Medpace Holdings and its competitors. Medpace Holdings's current Enterprise Value is €14,418 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (FRA:01P) is currently considered Modestly Overvalued. The stock's GF Value™ is €463.14, compared to a current price of €530.40 — trading 14.5% above its estimated fair value. The current Enterprise Value is €14,418 Mil. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Medpace Holdings (FRA:01P), the current Enterprise Value is €14,418 Mil as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (FRA:01P) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of €530.40 is trading 14.5% above its estimated GF Value™ of €463.14.
GuruFocus considers Medpace Holdings to be Modestly Overvalued.
Key valuation signals for FRA:01P:
Enterprise Value: €14,418 Mil
GF Value™: €463.14 vs. price of €530.40 (14.5% above fair value)
No single metric tells the full story. See the FRA:01P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score
Get the complete analysis for FRA:01P
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:01P has been successfully added to your 
